https://www.selleckchem.com/products/mrtx849.html
In contrast, treatment with TNAP increased cranial bone volume (p less then 0.01), density (p less then 0.01) and mineral content (p less then 0.01) as compared to vehicle treated controls, but had no effect on craniosynostosis or malocclusion in BALB/c FGFR2C342Y/+ mice. These results indicate that postnatal recombinant TNAP enzyme therapy diminishes craniosynostosis severity in the C57BL/6 FGFR2C342Y/+ neonatal onset mouse model of Crouzon syndrome, and that effects of exogenous TNAP are genetic background dependent.Background Cogniti
Like
Comment
Share
